Content of online questionnaire on barriers and facilitators for HIV testing among patients with malignant lymphoma.

(DOCX)</p

Characteristics of included patients with malignant lymphoma in five hospitals in the region of Amsterdam, overall and by HIV testing within 3 months before and after malignant lymphoma diagnosis, treatment or work-up, 2015–2020.

Characteristics of included patients with malignant lymphoma in five hospitals in the region of Amsterdam, overall and by HIV testing within 3 months before and after malignant lymphoma diagnosis, treatment or work-up, 2015–2020.</p

Questionnaire responses on barriers and facilitators for HIV testing among patients with malignant lymphoma by 40 hematology physicians from 5 hospitals in the region of Amsterdam, 2020, ranked by statement score.

PWML: patients with malignant lymphoma.</p

Flowchart of identification, screening and inclusion of data of patients diagnosed with malignant lymphoma in five hospitals in the region of Amsterdam, 2015–2020.

*Reasons for exclusion were: no definitive lymphoma diagnosis (20%), lymphoma diagnosis and treatment prior completely took place before the study period (57%), diagnosed and treated for lymphoma all took place at another hospital (20%), and known HIV infection prior to lymphoma work-up and diagnosis (3%). NTH: Non-teaching hospital. TH: Teaching hospital. UH: University hospital.</p

Themes identified from semi-structured interviews with hematologists on their HIV testing behavior among lymphoma patients, and influencing factors.

Themes identified from semi-structured interviews with hematologists on their HIV testing behavior among lymphoma patients, and influencing factors.</p

Hematologists’ reflections on HIV testing among patients with malignant lymphoma and recommendations for improvement.

Hematologists’ reflections on HIV testing among patients with malignant lymphoma and recommendations for improvement.</p

Interview guide for semi-structured interviews with hematologists working in the region of Amsterdam on factors influencing HIV testing behavior among malignant lymphoma patients.

(DOCX)</p

Interview guide for semi-structured interviews with authors of hematology guidelines working in the region of Amsterdam on the extent of and reasons for HIV testing recommendations in malignant lymphoma guidelines.

(DOCX)</p